Acute pain

Branded Legacy, Inc. Launches New Delta 8 Product Line

Retrieved on: 
Wednesday, July 28, 2021

The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.

Key Points: 
  • The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.
  • Branded Legacys Vice President, Matthew Nichols quotes, Many of the retailers our sales team has contacted have requested Delta 8, and now we can fulfill this demand.
  • About Spikes CBDx: Spikes CBDx is a line of CBD products designed to assist athletes perform better, recover faster, and avoid injuries.
  • The CBD line also targets individuals who are looking for pain relief, better sleep, faster recovery and lowering inflammation.

KitoTech Medical Announces Jeff Willis Has Joined as Its Chief Commercial Officer

Retrieved on: 
Monday, July 26, 2021

SEATTLE, July 26, 2021 /PRNewswire-PRWeb/ --KitoTech Medical, manufacturer of the microMend Wound Closure Product, announces today that Jeff Willis, an experienced executive in the wound closure space, has joined KitoTech as its Chief Commercial Officer.

Key Points: 
  • SEATTLE, July 26, 2021 /PRNewswire-PRWeb/ --KitoTech Medical, manufacturer of the microMend Wound Closure Product, announces today that Jeff Willis, an experienced executive in the wound closure space, has joined KitoTech as its Chief Commercial Officer.
  • He brings over 20 years of commercial experience in the medical device industry.
  • From 2005 to 2021, Jeff was at Advanced Medical Solutions Group plc (AMS), an advanced wound closure and wound care company with a $850 million market cap.
  • Jeff has a unique background with experience in both of our markets - medical and consumer.

XRHealth and Reducept Offer Patients Virtual Reality Therapy for Pain Management

Retrieved on: 
Monday, July 26, 2021

BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.

Key Points: 
  • BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.
  • The virtual reality technology provides exercises that train people suffering from chronic pain on how to gain control over pain, potentially reducing the need for medication.
  • The Reducept VR Game trains the users' brain to create its own pain medication via digital psychological pain treatment.
  • XRHealth operates state-of-the-art therapeutic care Virtual Clinics, utilizing proprietary FDA and CE registered medical Extended Reality (XR) technology (virtual and augmented reality).

The Gulf Pain Management Drugs Industry is Expected to Reach $1+ Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021

The "Gulf Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gulf Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Gulf Pain Management Drugs Market was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%.
  • The length of the pain would range from acute pain for short term to chronic pain for long term.
  • The Gulf pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Retrieved on: 
Wednesday, July 21, 2021

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Retrieved on: 
Wednesday, July 21, 2021

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Canada’s surgery backlog could lead to wave of new chronic pain and opioid dependencies

Retrieved on: 
Wednesday, July 21, 2021

TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- As Canada’s vaccination rates climb and hospitals begin to tackle the mountain of postponed surgeries due to the pandemic, we are facing an echo epidemic of new chronic pain sufferers. Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system. However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.

Key Points: 
  • Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system.
  • However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.
  • The risk of chronic pain following surgery is high.
  • The risk may be further compounded by the current echo pandemic of mental health issues, as depression and anxiety significantly increase the risk of developing chronic pain after surgery.

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

Retrieved on: 
Tuesday, July 20, 2021

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain. Q-State will subsequently be eligible for an additional $1 million in grant funding based on successful completion of certain program milestones.

Key Points: 
  • Funded as part of the NIH HEAL InitiativeSM, the grant supports Q-States efforts to pursue analgesic treatment paradigms beyond those associated with opioids.
  • The company is currently advancing ASO candidates targeting Nav1.7, Nav1.8, or both channels using the companys AI-enabled computational neuroscience technology.
  • In addition to cancer pain, these ASO candidates also have potential applicability in the treatment of a variety of other moderate-to-severe pain states.
  • This grant was awarded by the National Institute of Cancer of the National Institutes of Health under Award Number R44CA247110.

As the Summer Heat Increases, So Does Your Chance of Getting a Kidney Stone

Retrieved on: 
Tuesday, July 20, 2021

BALTIMORE, July 20, 2021 /PRNewswire/ --Summer is officially here and so is kidney stone season.

Key Points: 
  • BALTIMORE, July 20, 2021 /PRNewswire/ --Summer is officially here and so is kidney stone season.
  • As a result, concentrated urine forms and there is less liquid to dissolve salts in the body, increasing chances of forming a stone.
  • Summer is officially here and so is kidney stone season.
  • More than 1 million people will have a kidney stone this year.

Rapid-Ease Offers Fast Pain Relief

Retrieved on: 
Tuesday, July 20, 2021

FORT LAUDERDALE, Fla., July 20, 2021 /PRNewswire/ --Rapid-Ease is a brand that has made its name in the pain relief industry.

Key Points: 
  • FORT LAUDERDALE, Fla., July 20, 2021 /PRNewswire/ --Rapid-Ease is a brand that has made its name in the pain relief industry.
  • The brand's Rapid-Ease Pain Relief Cream brings a particularly potent list of herbal ingredients delivered in therapeutic levels designed to genuinely "help you heal naturally."
  • Davies-Haycock's brands are founded on a commitment to creating fast-acting, effective topical pain relief products.
  • As a topical product, Rapid-Ease Pain Relief Cream has been carefully formulated by renowned natural cosmetic chemist Susan Hall to maximize absorption through a unique penetration system.